生脉饮联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭临床研究

Clinical Study on Shengmai Yin Combined with Sacubitril Valsartan Sodium Tablets for Chronic Heart Failure

目的:观察生脉饮联合沙库巴曲缬沙坦钠片对慢性心力衰竭患者N末端B型钠尿肽原(NT-proBNP)、细胞间黏附分子-1(s ICAM-1)、血浆脑钠肽(BNP)水平的影响。方法:选取80例慢性心力衰竭患者,按随机数字表法分为对照组和观察组各40例。对照组口服沙库巴曲缬沙坦钠片进行治疗,观察组在对照组基础上口服生脉饮。比较2组临床疗效及临床症状改善情况,分析治疗前后的心功能变化情况和NT-proBNP、sICAM-1、BNP水平。结果:观察组总有效率为97.50%,对照组为77.50%,2组比较,差异有统计学意义(P<0.05)。观察组乏力、下肢水肿、呼吸困难消失时间显著短于对照组,6 min步行距离显著长于对照组,差异均有统计学意义(P<0.05)。治疗前,2组左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)比较,差异无统计学意义(P>0.05)。治疗后,2组LVEF较治疗前上升,LVEDD和LVESD较治疗前下降(P<0.05);观察组LVEF高于对照组,LVEDD和LVESD低于对照组(P<0.05)。治疗前,2组NT-proBNP、sICAM-1、BNP水平比较,差异无统计学意义(P>0.05)。治疗后,2组NT-proBNP、sICAM-1、BNP水平较治疗前下降(P<0.05),观察组NT-proBNP、sICAM-1、BNP水平低于对照组(P<0.05)。结论:生脉饮联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭效果显著,可以明显改善患者的临床症状和心功能,降低NT-proBNP、sICAM-1、BNP水平。

Objective:To observe the effect of Shengmai yin combined with sacubitril valsartan sodium tablets on levels of N-terminal B-type natriuretic peptide(NT-proBNP),soluble intercelluar adhesion molecule-1(sICAM-1),and plasma brain natriuretic peptide(BNP)in patients with chronic heart failure.Methods:A total of 80 cases of patients with chronic heart failure were selected and divided into the control group and the observation group according to the random number table method,40 cases in each group.The control group was given oral administration of sacubitril valsartan sodium tablets,and the observation group was additionally given oral administration of Shengmai yin based on the treatment of the control group.The clinical effect and improvement of clinical symptoms were compared between the two groups.The change in the heart function before and after treatment and levels of NT-proBNP,sICAM-1,and BNP were analyzed.Results:The total effective rate was 97.50% in the observation group and 77.50% in the control group,the difference being significant(P<0.05).The disappearance time of lack of strength,lower extremity edema,and dyspnea in the observation group was significantly earlier than that in the control group,and 6-minute walking distance was significantly longer,differences being significant(P<0.05).Before treatment,when compared left ventricle ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),and left ventricular end-systolic diameter(LVESD)between the two groups,there was no significance in the difference(P>0.05).After treatment,LVEF levels in the two groups were increased when compared with those before treatment,and LVEDD and LVESD were decreased(P<0.05).After treatment,LVEF in the observation group was higher than that in the control group,and LVEDD and LVESD were lower(P<0.05).Before treatment,when compared levels of NT-proBNP,sICAM-1,and BNP between the two groups,there was no significance in the difference(P>0.05).After treatment,levels of NT-proBNP,sICAM-1,and BNP in the two groups were decreased when compared with those before treatment(P<0.05),and the three levels in the observation group were lower than those in the control group(P<0.05).Conclusion:The therapy of Shengmai yin combined with sacubitril valsartan sodium tablets has a significant curative effect in the treatment of chronic heart failure.It can significantly improve clinical symptoms and the heart function,and reduce levels of NT-proBNP,sICAM-1,and BNP.